Immunogenicity of COVID-19 mRNA Vaccines in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
David Helfgott(Cornell University), Gail J. Roboz(Cornell University), Sabrina Racine‐Brzostek(NewYork–Presbyterian Hospital), Paul J. Christos(Cornell University), Tina Niu(NewYork–Presbyterian Hospital), Michael S. Samuel(Cancer Research UK Scotland Institute), Itzel Nino(NewYork–Presbyterian Hospital), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Zhen Zhao(Cornell University), Jorge Contreras(NewYork–Presbyterian Hospital), Kelsey J. Short(NewYork–Presbyterian Hospital)
Cited by 2
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k